Versanis Bio is a technology company.
Versanis Bio has raised $70.0M across 1 funding round.
Versanis Bio has raised $70.0M in total across 1 funding round.
Versanis Bio is a clinical-stage biopharmaceutical company focused on developing transformative treatments for cardiometabolic diseases, particularly obesity. Its lead product candidate, bimagrumab, is a first-in-class monoclonal antibody targeting activin type II receptors to reduce fat while building muscle, addressing a critical gap in obesity treatment by improving body composition rather than just weight loss. Versanis serves patients living with obesity and related metabolic disorders, aiming to provide more effective and durable therapeutic options. The company has demonstrated growth momentum through a $70 million Series A financing in 2021 and was acquired by Eli Lilly in 2023, reflecting strong validation of its clinical and scientific approach[1][2][3][6].
Founded in 2021 by biotech investment firm Aditum Bio, Versanis Bio emerged from the in-licensing of bimagrumab from Novartis to develop novel therapies for metabolic diseases and obesity. The company quickly attracted significant investment, with Medicxi and Atlas Venture co-leading its $70 million Series A round. Key figures include Mark Pruzanski, M.D., chairman and CEO, who brought leadership experience from Intercept Pharmaceuticals. Early traction was marked by advancing bimagrumab into Phase 2 clinical trials (BELIEVE study), alone or combined with semaglutide, to evaluate its efficacy in fat loss and muscle gain in overweight or obese adults. The acquisition by Eli Lilly in 2023 further accelerated its development trajectory[1][3][6][7].
Versanis Bio is positioned at the intersection of two major trends: the rising global obesity epidemic and the shift toward precision biologics that target metabolic pathways more effectively. The timing is critical as obesity affects over 100 million Americans and is linked to numerous chronic diseases. By targeting activin receptors, Versanis addresses a novel biological mechanism, potentially transforming obesity treatment beyond traditional appetite suppression or calorie restriction. Its integration with Lilly’s incretin therapies reflects a broader industry movement toward combination treatments that improve patient outcomes. Versanis thus contributes to expanding the therapeutic landscape for cardiometabolic diseases and influences the ecosystem by validating activin biology as a drug target[2][3][7].
Looking ahead, Versanis Bio’s future is closely tied to the clinical success of bimagrumab, especially in combination with incretin drugs like semaglutide. If Phase 2b trials confirm improved fat loss with muscle preservation, it could redefine standards of care for obesity and related metabolic conditions. The trend toward biologics and combination therapies will likely shape their journey, with growing emphasis on personalized medicine and durable outcomes. As part of Eli Lilly, Versanis has the infrastructure to scale development and commercialization globally. Its influence may expand by pioneering new pathways in metabolic disease treatment and inspiring further innovation in activin receptor-targeted therapies[3][7].
Versanis Bio has raised $70.0M in total across 1 funding round.
Versanis Bio's investors include Access Biotechnology, Aditum Bio, Atlas Venture, Canaan Partners, RA Capital.
Versanis Bio has raised $70.0M across 1 funding round. Most recently, it raised $70.0M Series A in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2021 | $70.0M Series A | Access Biotechnology, Aditum Bio, Atlas Venture, Canaan Partners, RA Capital |